BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Belantamab mafodotin readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Belantamab mafodotin\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05055063-3152@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20270202
DTEND;VALUE=DATE:20270203
SUMMARY:Belantamab mafodotin: Phase 1 readout est. (NCT05055063)
DESCRIPTION:Belantamab mafodotin\, phase 1\, Multiple Myeloma.\nStudy: A Ph
 ase 1 With Extension Cohort\, Single Arm\, Single Center\, Open Label Tria
 l of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multip
 le Myeloma\nEstimated primary completion: 2 February 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05055063
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05145816-3152@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Belantamab mafodotin: Phase 1/2 readout est. (NCT05145816)
DESCRIPTION:Belantamab mafodotin\, phase 1/2.\nStudy: Phase 1/2a Study of B
 elantamab Mafodotin in Relapsed or Refractory AL Amyloidosis\nEstimated pr
 imary completion: 1 March 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/belantamab-mafodotin#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05145816
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05853965-3152@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Belantamab mafodotin: Phase 1/2 readout est. (NCT05853965)
DESCRIPTION:Belantamab mafodotin\, phase 1/2\, Multiple Myeloma.\nStudy: Co
 mbination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of
  Relapsed and Refractory t(11\;14) Multiple Myeloma\nEstimated primary com
 pletion: April 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 belantamab-mafodotin#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05853965
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02343042-3152@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Belantamab mafodotin: Phase 1/2 readout est. (NCT02343042)
DESCRIPTION:Belantamab mafodotin\, phase 1/2\, Multiple Myeloma.\nStudy: Se
 linexor and Backbone Treatments of Multiple Myeloma Patients\nEstimated pr
 imary completion: April 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/belantamab-mafodotin#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT02343042
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03715478-3152@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Belantamab mafodotin: Phase 1/2 readout est. (NCT03715478)
DESCRIPTION:Belantamab mafodotin\, phase 1/2\, Multiple Myeloma.\nStudy: Mu
 lti-Center Study of GSK2857916 in Combination With Pomalidomide and Dex\nE
 stimated primary completion: 1 June 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/belantamab-mafodotin#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT03715478
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07742527-3152@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20270805
DTEND;VALUE=DATE:20270806
SUMMARY:Belantamab mafodotin: Phase 1 readout est. (NCT07742527)
DESCRIPTION:Belantamab mafodotin\, phase 1\, Multiple Myeloma.\nStudy: A St
 udy to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Int
 ravenous Belantamab in Participants With Multiple Myeloma While Treated Wi
 th Standard of Care\nEstimated primary completion: 5 August 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/belantamab-mafodotin#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07742527
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04643002-3152@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20270913
DTEND;VALUE=DATE:20270914
SUMMARY:Belantamab mafodotin: Phase 1/2 readout est. (NCT04643002)
DESCRIPTION:Belantamab mafodotin\, phase 1/2\, Multiple Myeloma.\nStudy: Is
 atuximab in Combination With Novel Agents in RRMM - Master Protocol\nEstim
 ated primary completion: 13 September 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT04643002
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05556798-3152@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Belantamab mafodotin: Phase 1 readout est. (NCT05556798)
DESCRIPTION:Belantamab mafodotin\, phase 1\, Multiple Myeloma.\nStudy: A St
 udy of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidom
 ide in People With Multiple Myeloma That Has Not Responded to Treatment or
  Has Come Back After Treatment\nEstimated primary completion: October 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/belantamab-mafodoti
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 556798
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05208307-3152@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20271021
DTEND;VALUE=DATE:20271022
SUMMARY:Belantamab mafodotin: Phase 2 readout est. (NCT05208307)
DESCRIPTION:Belantamab mafodotin\, phase 2\, Multiple Myeloma.\nStudy: Bela
 ntamab Mafodotin\, Pomalidomide and Dexamethasone for the Treatment of Hig
 h-Risk Myeloma\nEstimated primary completion: 21 October 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05208307
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05091372-3152@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Belantamab mafodotin: Phase 2 readout est. (NCT05091372)
DESCRIPTION:Belantamab mafodotin\, phase 2\, Multiple Myeloma.\nStudy: Mini
 mal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin 
 and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Pa
 tients With Newly Diagnosed Multiple Myeloma\nEstimated primary completion
 : 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/b
 elantamab-mafodotin#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05091372
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07612787-3152@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Belantamab mafodotin: Phase 1/2 readout est. (NCT07612787)
DESCRIPTION:Belantamab mafodotin\, phase 1/2\, Multiple Myeloma.\nStudy: A 
 Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With
  Relapsed Multiple Myeloma\nEstimated primary completion: 1 January 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/belantamab-mafodotin#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0761
 2787
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05789303-3152@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Belantamab mafodotin: Phase 2 readout est. (NCT05789303)
DESCRIPTION:Belantamab mafodotin\, phase 2\, Multiple Myeloma.\nStudy: Stud
 y of Belantamab Mafodotin With Carfilzomib\, Pomalidomide\, and Dexamethas
 one in Relapsed Multiple Myeloma\nEstimated primary completion: 1 July 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/belantamab-mafodot
 in#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5789303
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05714839-3152@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20280803
DTEND;VALUE=DATE:20280804
SUMMARY:Belantamab mafodotin: Phase 1/2 readout est. (NCT05714839)
DESCRIPTION:Belantamab mafodotin\, phase 1/2\, Multiple Myeloma.\nStudy: A 
 Study to Investigate the Safety and Efficacy of Belantamab for the Treatme
 nt of Multiple Myeloma When Used as Monotherapy and in Combination Treatme
 nts\nEstimated primary completion: 3 August 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05714839
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04808037-3152@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20280908
DTEND;VALUE=DATE:20280909
SUMMARY:Belantamab mafodotin: Phase 1/2 readout est. (NCT04808037)
DESCRIPTION:Belantamab mafodotin\, phase 1/2\, Multiple Myeloma.\nStudy: Bl
 mf\, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With
  Newly Diagnosed Multiple Myeloma\nEstimated primary completion: 8 Septemb
 er 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/belantamab-m
 afodotin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT04808037
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05922501-3152@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Belantamab mafodotin: Phase 2 readout est. (NCT05922501)
DESCRIPTION:Belantamab mafodotin\, phase 2\, Multiple Myeloma.\nStudy: Isat
 uximab\, Bela Maf\, Pom\, and Dex in Relapsed/Refractory Multiple Myeloma\
 nEstimated primary completion: 31 December 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05922501
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07614360-3152@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Belantamab mafodotin: Phase 2 readout est. (NCT07614360)
DESCRIPTION:Belantamab mafodotin\, phase 2\, Multiple Myeloma.\nStudy: Stud
 y of Alternative and Approved Dosing Regimens of Belantamab Mafodotin\, Bo
 rtezomib\, and Dexamethasone (BVd) in Participants With Relapsed/Refractor
 y Multiple Myeloma\nEstimated primary completion: 28 February 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/belantamab-mafodotin#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07614360
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04822337-3152@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Belantamab mafodotin: Phase 1/2 readout est. (NCT04822337)
DESCRIPTION:Belantamab mafodotin\, phase 1/2\, Multiple Myeloma.\nStudy: St
 udy of Carfilzomib\, Lenalidomide\, Dexamethasone and Belantamab Mafodotin
  in Multiple Myeloma\nEstimated primary completion: April 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT04822337
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05847569-3152@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20290629
DTEND;VALUE=DATE:20290630
SUMMARY:Belantamab mafodotin: Phase 2 readout est. (NCT05847569)
DESCRIPTION:Belantamab mafodotin\, phase 2\, Multiple Myeloma.\nStudy: Alte
 rnate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of 
 Triple-Class Refractory Multiple Myeloma\nEstimated primary completion: 29
  June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/belantama
 b-mafodotin#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05847569
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07844200-3152@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20300228
DTEND;VALUE=DATE:20300301
SUMMARY:Belantamab mafodotin: Phase 2 readout est. (NCT07844200)
DESCRIPTION:Belantamab mafodotin\, phase 2.\nStudy: The Primary Objective o
 f the Trial is to Evaluate the Effect of the Addition of Belantamab Mafodo
 tin to Standard of Care Therapy on the Titres of Serum Anti-dsDNA Antibodi
 es in Patients With Previously Treated SLE.\nEstimated primary completion:
  February 2030. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/belan
 tamab-mafodotin#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07844200
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07720843-3152@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Belantamab mafodotin: Phase 1 readout est. (NCT07720843)
DESCRIPTION:Belantamab mafodotin\, phase 1\, Multiple Myeloma.\nStudy: TAlq
 uetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (
 TaBleMM)\nEstimated primary completion: March 2030. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07720843
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227311-3152@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20300830
DTEND;VALUE=DATE:20300831
SUMMARY:Belantamab mafodotin: Phase 2 readout est. (NCT07227311)
DESCRIPTION:Belantamab mafodotin\, phase 2\, Multiple Myeloma.\nStudy: A St
 udy to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combina
 tion With Standard of Care in Participants With Relapsed-Refractory Multip
 le Myeloma (RRMM)\nEstimated primary completion: 30 August 2030. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07227311
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06679101-3152@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20310428
DTEND;VALUE=DATE:20310429
SUMMARY:Belantamab mafodotin: Phase 3 readout est. (NCT06679101)
DESCRIPTION:Belantamab mafodotin\, phase 3\, Multiple Myeloma.\nStudy: A St
 udy of Belantamab Mafodotin Administered in Combination With Lenalidomide 
 and Dexamethasone (BRd) Versus Daratumumab\, Lenalidomide\, and Dexamethas
 one (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who
  Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)\nEstima
 ted primary completion: 28 April 2031. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/belantamab-mafodotin#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06679101
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07609706-3152@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20310822
DTEND;VALUE=DATE:20310823
SUMMARY:Belantamab mafodotin: Phase 1 readout est. (NCT07609706)
DESCRIPTION:Belantamab mafodotin\, phase 1\, Multiple Myeloma.\nStudy: A St
 udy of the Combination of Belantamab Mafodotin\, Bortezomib\, and Dexameth
 asone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Imp
 airment\nEstimated primary completion: 22 August 2031. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07609706
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07285239-3152@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20311130
DTEND;VALUE=DATE:20311201
SUMMARY:Belantamab mafodotin: Phase 3 readout est. (NCT07285239)
DESCRIPTION:Belantamab mafodotin\, phase 3\, Multiple Myeloma.\nStudy: Bela
 ntamab Mafodotin or Daratumumab With Bortezomib\, Lenalidomide and Dexamet
 hasone for Newly Diagnosed Multiple Myeloma\nEstimated primary completion:
  November 2031. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/belan
 tamab-mafodotin#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07285239
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07831122-3152@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20330131
DTEND;VALUE=DATE:20330201
SUMMARY:Belantamab mafodotin: Phase 1 readout est. (NCT07831122)
DESCRIPTION:Belantamab mafodotin\, phase 1\, Multiple Myeloma.\nStudy: Stud
 y of Belantamab Mafodotin\, Cevostamab\, Pomalidomide for RRMM Patients (M
 APLE)\nEstimated primary completion: January 2033. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07831122
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07224672-3152@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20330112
DTEND;VALUE=DATE:20330113
SUMMARY:Belantamab mafodotin: Phase 2 readout est. (NCT07224672)
DESCRIPTION:Belantamab mafodotin\, phase 2.\nStudy: A Study to Evaluate the
  Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophos
 phamide\, Bortezomib\, and Dexamethasone in Adult Participants With Newly 
 Diagnosed Amyloid Light Chain (AL) Amyloidosis\nEstimated primary completi
 on: 12 January 2033. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 belantamab-mafodotin#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07224672
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07748689-3152@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20330331
DTEND;VALUE=DATE:20330401
SUMMARY:Belantamab mafodotin: Phase 2 readout est. (NCT07748689)
DESCRIPTION:Belantamab mafodotin\, phase 2\, Multiple Myeloma.\nStudy: Comp
 aring Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomid
 e and Dexamethasone in Relapsed or Refractory Multiple Myeloma.\nEstimated
  primary completion: March 2033. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/belantamab-mafodotin#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07748689
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
